Velinotamig (BCMAxCD3 bispecific T cell engager): Autoimmune diseases (The Manila Times) - Jan 8, 2026 - "In December 2025, Genrix Bio initiated a Phase 1 study in China in patients with autoimmune diseases, and initial clinical data from the study will be shared in Q4 2026. Cullinan intends to use the data generated to accelerate global clinical development of the program. Following the completion of the Genrix Bio Phase 1 study, Cullinan will conduct all further development of velinotamig in autoimmune diseases."
P1 data • Trial status • Immunology
|